Key result
Adverse SDOH linked to ~27% higher mortality risk in prostate cancer.
Why the study?
Social determinants of health influence health outcomes, but their long-term effects on prostate cancer patients remain underexplored.
Does the presence of adverse social determinants of health worsen mortality and survival in patients with prostate cancer?
Cohort (n=25,252)
Yes
Does the presence of adverse social determinants of health worsen mortality and survival in patients with prostate cancer?
Adverse social determinants of health are significantly associated with increased mortality, poorer survival, and heightened sepsis risk in patients with prostate cancer.
Answers are grounded in this paper and cite their sources.
Adverse SDOH linked to worse prostate cancer survival; hypothesis-generating for interventions and should not yet change practice.
12119 Background: Social determinants of health (SDOH) such as housing instability, food insecurity, and low income are known to influence health outcomes, but their long-term effects on prostate cancer (PCa) patients remain underexplored. To compare long-term outcomes, including mortality, sepsis, sexual dysfunction, and comorbidities across major organ systems, between prostate cancer patients with and without adverse SDOH. Methods: Retrospective cohort study using the TriNetX federated database (deprecated COVID-19 Research Network, 88 healthcare organizations). Cohort 1 included adults (≥18 years) with PCa (ICD-10-CM C61) and at least one adverse SDOH code (n = 14,595). Cohort 2 included PCa patients without SDOH codes (n = 875,545). Propensity score matching (1:1) balanced cohorts on demographics, external morbidity causes, ECOG status, and BMI (final n = 12,626 per cohort). The index event was the first prostate cancer diagnosis (with SDOH for Cohort 1). Outcomes assessed from 1-day post-index onward (up to 20 years prior exclusion). Risk ratios (RR), hazard ratios (HR) from Kaplan-Meier survival, and mean instances via t-tests for mortality, severe sepsis, sexual dysfunction, and diseases of genitourinary, circulatory, endocrine/metabolic, respiratory, digestive, and infectious systems. Results: After matching, cohorts were balanced (mean age ~72 years, ~56% White, ~25% Black). PCa with adverse SDOH had higher mortality risk (22.0% vs 17.3%; RR 1.272 [95% CI, 1.209-1.338]; p < 0.001) and worse survival (median 2821 vs 5246 days; HR 2.018 [95% CI, 1.906-2.137]; p < 0.001). Severe sepsis risk was elevated (5.6% vs 4.7%; RR 1.199 [95% CI, 1.074-1.339]; p < 0.001; HR 1.824 [95% CI, 1.626-2.047]; p < 0.001). Sexual dysfunction risk was lower (0.2% vs 0.4%; RR 0.493 [95% CI, 0.305-0.794]; p = 0.003). For comorbidities, PCa with adverse SDOH showed mixed risks—genitourinary diseases had a lower risk but poorer survival (HR 1.113, 95% CI 1.017-1.218, p = 0.020); circulatory diseases showed equivalent risk but worse survival (HR 1.223, 95% CI 1.089-1.374, p = 0.001); endocrine/nutritional/metabolic conditions had similar risk but reduced survival (HR 1.277, 95% CI 1.151-1.418, p < 0.001); respiratory diseases had equivalent risk but poorer survival (HR 1.531, 95% CI 1.416-1.656, p < 0.001); digestive diseases demonstrated lower risk with worse survival (HR 1.308, 95% CI 1.200-1.425, p < 0.001). Conclusions: Adverse SDOH are associated with increased mortality and poorer survival in prostate cancer, alongside heightened sepsis risk and differential comorbidity patterns. Interventions targeting SDOH may improve long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) conducted a cohort in Prostate cancer (n=25,252). Adverse social determinants of health (SDOH) vs. No adverse SDOH codes was evaluated on Mortality (RR 1.272, 95% CI 1.209-1.338, p=< 0.001). Adverse social determinants of health in prostate cancer increased mortality risk compared to no adverse SDOH.
Synapse has enriched 10 related papers. Consider them for comparative context: